Market
Will Gilead announce a price reduction for lenacapavir in middle-income countries by 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Gilead official announcements and press releases
Story
Gilead's Lenacapavir: Science's 2024 Breakthrough for HIV Prevention
Dec 13, 2024, 07:30 AM
Gilead Sciences' lenacapavir, a long-acting injectable drug for HIV prevention, has been named the 2024 Breakthrough of the Year by the journal Science. Lenacapavir, which requires only a single shot every six months, demonstrated near-perfect efficacy in clinical trials, preventing HIV infections in 99.9% of participants. The drug targets the HIV capsid, disrupting key stages of viral replication, offering a novel mechanism of action. This development is seen as a significant step towards reducing the global HIV/AIDS epidemic. However, the high cost of lenacapavir poses a potential barrier to its widespread use, particularly in low-income regions. Gilead has made agreements to produce generic versions for 120 of the world's poorest countries, but middle-income nations like Brazil are excluded, sparking concerns about access and affordability.
View original story
Similar markets
No • 50%
Yes • 50%
No • 50%
Yes • 50%
More than 120 • 25%
50 to 80 • 25%
Less than 50 • 25%
81 to 120 • 25%
Regulatory approval • 25%
Distribution • 25%
Adherence • 25%
Cost • 25%
Gilead Sciences • 25%
Global Fund • 25%
PEPFAR • 25%
Other • 25%
CVS • 33%
Cigna • 33%
UnitedHealth • 33%
No significant reduction • 1%